에이치엘비는 끊임없는 열정과 노력으로 다양한 사업분야에서
미래의 변화를 주도하고 있습니다.
TARGETED THERAPY Apatinib — new third-line option for refractory gastric or GEJ cancer
Author : Toru Aoyama & Takaki Yoshikawa
Source : NATURE-REVIEWS
Apatinib significantly improves both the progression-free survival (PFS) and overall survival in patients with advanced-stage gastric cancer who are
refractory to two or more lines of chemotherapy. In the context of previous phase III trials of angiogenesis inhibitors for this disease, we discuss the role
of apatinib, and the advantages and limitations of VEGFR‑2 blockade in the advanced disease setting.